Fourth Affiliated Hospital of Zhejiang University
浙江大学医学院附属第四医院
Listed for 7 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Fourth Affiliated Hospital of Zhejiang University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌6 papers led
- Lung cancer肺癌9 papers led3 open trials led
- Osteosarcoma骨肉瘤0 papers led
- Coronary heart disease冠心病2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- IgA nephropathyIgA 肾病1 paper led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变4 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 6 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.04%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Hangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led6
- A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma.
- Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma.
- Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma.
- Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle.
- Robust radiosensitization of hemoglobin-curcumin nanoparticles suppresses hypoxic hepatocellular carcinoma.
- Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Lung cancer
肺癌Led 9 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.04%.
11 hospitals in Hangzhou for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingResearch on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06458894
Age 60 years to 99 years (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- RecruitingAnalysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
- Phase
- Not given
- Started
- 2018-01
- Posted
- Registry
- NCT05636605
Age 18 years to 80 years (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- Not yet recruitingEfficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07545213
Age 18 years to Not stated (registered criteria)
Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou
- Not yet recruitingVideo Double-Lumen Tube for Secondary Pulmonary Resection
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07467005
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led9
- Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.
- Identification of ATAD3A as a key regulator in non-small cell lung cancer by promoting STAT3-induced cell proliferation and tumor angiogenesis.
- Endobronchial ultrasound-guided transbronchial needle aspiration in peripheral pulmonary lesions: a systematic review and meta-analysis.
- Radionuclide-based theranostics - a promising strategy for lung cancer.
- Circulating insulin-like growth factor-1 and risk of lung diseases: A Mendelian randomization analysis.
- The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer.
- Nanomedicine-based adjuvant therapy: a promising solution for lung cancer.
- Metal Nanoparticles as Novel Agents for Lung Cancer Diagnosis and Therapy.
- Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status8
- Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
- Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
- Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
- Study of Furmonertinib as Follow-Up Treatment After Surgery for Early-Stage EGFR-Positive Lung Cancer: Real-World Observation
- Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
- Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung Cancer
- Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
- Video Double-Lumen Tube for Secondary Pulmonary Resection
Cancer
Osteosarcoma
骨肉瘤Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
20 hospitals in Hangzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
Other diseases
Coronary heart disease
冠心病Led 2 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.04%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Hangzhou for coronary heart disease231 hospitals in China for coronary heart disease
No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
- Temporal trends and risk factors of perioperative cardiac events in patients over 80 years old with coronary artery disease undergoing noncardiac surgery: a high-volume single-center experience, 2014-2022.
- Traditional Chinese Medicine for Patients of Coronary Artery Disease: Savior or Troublemaker? A Cohort Study About the Adherence to Antiplatelet Therapy.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Hangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Hangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 4 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 7.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led4
- Vitamin A treatment restores vision failures arising from Leber's hereditary optic neuropathy-linked mtDNA mutation.
- Leber's hereditary optic neuropathy-associated ND1 3733G>C mutation ameliorates the mitochondrial quality control and cellular homeostasis.
- Nuclear modifier YARS2 allele correction restored retinal ganglion cells-specific deficiencies in Leber's hereditary optic neuropathy.
- Optimized allotopic expression of mitochondrial ND6 transgene restored complex I and apoptosis deficiencies caused by LHON-linked ND6 14484T > C mutation.
Chinese-language papers (not in the count)1
Getting in touch
Name card to show staff or a driver
浙江大学医学院附属第四医院
Fourth Affiliated Hospital of Zhejiang University
杭州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.